Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours.

[1]  A. Haynes,et al.  Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer , 2013, Cancer.

[2]  S. Fosså,et al.  Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Norton,et al.  Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. , 2012, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[4]  C. Kollmannsberger,et al.  Classical clinical trial design in testicular cancer: time to move on. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Eggener,et al.  Global trends in testicular cancer incidence and mortality. , 2011, European urology.

[6]  T. Powles,et al.  Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Wahlqvist,et al.  Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Miranda,et al.  Suboptimal survival of male germ-cell tumors in southern Portugal--a population-based retrospective study for cases diagnosed in 1999 and 2000. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  G. Duncan,et al.  Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Andrew Kramar,et al.  Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Culine,et al.  Management of testicular neoplasms in France and compliance with national guidelines. , 2010 .

[12]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[13]  S. Daneshmand,et al.  Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Fosså,et al.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. , 2008, European urology.

[15]  R. de Wit,et al.  Controversies in the management of clinical stage I testis cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Théodore,et al.  The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area , 2005, British Journal of Cancer.

[17]  W. Siegert,et al.  European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  I. Ray-Coquard,et al.  Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  R. Grimer,et al.  Should Soft Tissue Sarcomas be Treated at a Specialist Centre? , 2003, Sarcoma.

[20]  L. Collette,et al.  Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. , 1999, Journal of the National Cancer Institute.

[21]  A. Rydholm.  Improving the management of soft tissue sarcoma , 1998, BMJ.

[22]  S. Culine,et al.  Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  K. Tilling,et al.  Variable management of soft tissue sarcoma: Regional audit with implications for specialist care , 1997, The British journal of surgery.

[24]  Richard Sylvester,et al.  International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .

[25]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .